The DOI matches its Crossref record.
Reactive Hyperreninemia Is a Major Determinant of Plasma Angiotensin II During ACE Inhibition
Abstract
The new ACE inhibitor trandolapril was administered to normal volunteers at daily doses of 0.5, 2, and 8 mg for 10 days. Twenty-one volunteers, aged 21-30 years, were included in the study. To randomly selected groups of seven subjects, each dose was administered in a single-blind fashion. None of the doses induced a consistent fall in blood pressure. Angiotensin-converting enzyme activity (ACE) was measured in vitro using three different synthetic substrates (i.e., Hip-Gly-Gly, Z-Phe-His-Leu, or angiotensin I). Although the degree of ACE inhibition assessed with the three methods varied widely, all methods clearly indicated dose-dependent ACE inhibition. These in vitro results were confirmed by measuring ACE inhibition in vivo using the ratio of plasma angiotensin II (ANG II) to blood angiotensin I (ANG I). The dose-dependent ACE inhibition was paralleled by a dose-dependent rise in active renin and blood angiotensin I levels, most evident on day 10. In contrast, plasma ANG II levels on day 10 were not different whether the volunteers received 0.5 or 8 mg trandolapril. Thus, whereas increasing doses of this new ACE inhibitor progressively enhanced the blockade of ACE activity, this was not reflected by additional reductions of plasma ANG II levels. The progressive enhancement of ACE inhibition seemed to be offset by the accentuation of the compensatory rise in renin and ANG I, which was still partially converted to ANG II.(ABSTRACT TRUNCATED AT 250 WORDS)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
MacFadyen, R. (1997) · Cardiovascular Research · doi:10.1016/s0008-6363(97)00091-6 · Cited by 339
Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides.
Campbell, D. J., Kladis, A., & Duncan, A. M. (1994) · Hypertension · doi:10.1161/01.hyp.23.4.439 · Cited by 317
Schmitt, F., Martinez, F., Brillet, G., Nguyen-Khoa, T., Brouard, R., Sissmann, J., Lacour, B., & Grunfeld, J.-P. (1998) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-199802000-00019 · Cited by 21
Metadata
- Authors
- Mooser, V., Nussberger, J., Juillerat, L., Burnier, M., Waeber, B., Bidiville, J., Pauly, N., & Brunner, H. R.
- Venue
- Journal of Cardiovascular Pharmacology
- Published
- 1990-02
- Volume
- 15
- Issue
- 2
- Pages
- 276-282
- ISSN
- 0160-2446 (ISSN-L)
- OpenAlex
- W2026885101
- Cited by
- 170
- References
- 0
- FWCI
- 6.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Reactive Hyperreninemia Is a Major Determinant of Plasma Angiotensin II During ACE Inhibition. https://app.cochat.ai/papers/10.1097/00005344-199002000-00015
- The paper
- Mooser, V., Nussberger, J., Juillerat, L., Burnier, M., Waeber, B., Bidiville, J., Pauly, N., & Brunner, H. R. (1990). Reactive Hyperreninemia Is a Major Determinant of Plasma Angiotensin II During ACE Inhibition. Journal of Cardiovascular Pharmacology. https://doi.org/10.1097/00005344-199002000-00015
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.